Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M, Jares P, Sanfeliu E, Villacampa G, Hernández-Lllán E, Martínez-Puchol AI, Shankar S, González-Farré B, Waks AG, Brasó-Maristany F, Pardo F, Manning DK, Abery JA, Curaba J, Moon L, Gordon O, Galván P, Wachirakantapong P, Castillo O, Nee CM, Blasco P, Senevirathne TH, Sirenko V, Martínez-Sáez O, Aguirre A, Krop IE, Li Z, Spellman P, Metzger Filho O, Polyak K, Michaels P, Puig-Butillé JA, Vivancos A, Matito J, Buckingham W, Perou CM, Villagrasa-González P, Prat A, Parker JS, Paré L. Marín-Aguilera M, et al. Among authors: metzger filho o. ESMO Open. 2024 Mar;9(3):102903. doi: 10.1016/j.esmoop.2024.102903. Epub 2024 Mar 6. ESMO Open. 2024. PMID: 38452436 Free PMC article.
SnapShot: breast cancer.
Polyak K, Metzger Filho O. Polyak K, et al. Among authors: metzger filho o. Cancer Cell. 2012 Oct 16;22(4):562-562.e1. doi: 10.1016/j.ccr.2012.06.021. Cancer Cell. 2012. PMID: 23079664 Free article. No abstract available.
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K. Li Z, et al. Among authors: metzger filho o. J Clin Invest. 2024 Feb 1;134(7):e176454. doi: 10.1172/JCI176454. J Clin Invest. 2024. PMID: 38300710 Free PMC article. Clinical Trial.
Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O, Winer EP, Krop I. Metzger-Filho O, et al. Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Clin Cancer Res. 2013. PMID: 23942091 Review.
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. Janiszewska M, et al. Among authors: metzger filho o. JCI Insight. 2021 Jun 8;6(11):e147617. doi: 10.1172/jci.insight.147617. JCI Insight. 2021. PMID: 33886505 Free PMC article.
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Vaz-Luis I, et al. Among authors: metzger filho o. Clin Breast Cancer. 2013 Aug;13(4):254-63. doi: 10.1016/j.clbc.2013.02.010. Clin Breast Cancer. 2013. PMID: 23829891 Free PMC article.
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, Walker L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Metzger Filho O, et al. Ann Oncol. 2020 Sep;31(9):1231-1239. doi: 10.1016/j.annonc.2020.05.014. Epub 2020 May 24. Ann Oncol. 2020. PMID: 32461105 Free article. Clinical Trial.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart MJ, de Azambuja E. Lambertini M, et al. Among authors: metzger filho o. ESMO Open. 2020 Nov;5(6):e000979. doi: 10.1136/esmoopen-2020-000979. ESMO Open. 2020. PMID: 33154022 Free PMC article. Clinical Trial.
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M. Metzger-Filho O, et al. J Clin Oncol. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589556 Clinical Trial.
64 results